Toxic epidermal necrosishttps://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis
Toxic epidermal necrosis imhando yeganda rakanyanya kuita. Zviratidzo zvekutanga zvinosanganisira fivha uye zviratidzo zvakaita sefuruu. Mazuva mashomanana gare gare ganda rinotanga kunyunguduka uye kusvuura kuumba nzvimbo dzinorwadza dzine ganda. Izvo zvakakosha kuti mucous membranes, senge muromo, anowanzo kubatanidzwa. Zvinetso zvinosanganisira kupera mvura mumuviri, sepsis, mabayo, uye kutadza kwenhengo dzakawanda.

Chinonyanya kukonzera mimwe mishonga yakadai selamotrigine, carbamazepine, allopurinol, sulfonamide antibiotics, uye nevirapine. Zvinhu zvine njodzi zvinosanganisira HIV uye systemic lupus erythematosus. Kurapwa kunowanzoitwa muchipatara senge muyuniti yekutsva kana mukamuri yevanorwara zvakanyanya.

Kurapwa
Ichi chirwere chakakomba, saka kana miromo yako kana muromo wako zvakakanganisika kana ganda rako rikaita blistered, ona chiremba wako nekukurumidza.
Mishonga inofungirwa inofanira kuregedzwa. (semuenzaniso maantibiotic, asiri-steroidal anti-inflammatory drugs)

☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
  • Hunhu kurasikirwa kweganda reToxic epidermal necrosis
  • TENS ― zuva rechi10
  • Necrolysis epidermalis toxica
  • Early-stage blisters inogona kukurumidza kufambira mberi kuti isanganise muviri wese mukati memazuva mashoma.
References Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management 34577817 
NIH
Stevens-Johnson Syndrome (SJS) uye Toxic Epidermal Necrolysis (TEN) haawanzo mamiriro apo ganda rinosangana necrosis yakakura uye kudurura. Mukutaura kwekurapa, cyclosporine inonyanya kushanda kune SJS, nepo kusanganiswa kwe intravenous immunoglobulin (IVIg) uye corticosteroids inoshanda zvakanakisisa kune zviitiko zveSJS neTEN.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
 Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 36469487
Toxic epidermal necrolysis (TEN) idambudziko rakakomba reganda rinokonzerwa nemimwe mishonga uye immune system basa, zvichikonzera kurumwa kukuru kwekunze kweganda rekunze (epidermis) , kunokanganisa kupfuura 30% yemuviri. TEN ine huwandu hwevanhu vanofa vanodarika 20%, kazhinji nekuda kwehutachiona uye kutadza kufema. Kumisa mushonga unokonzera maitiro, kupa rubatsiro rwekutsigira, uye kushandisa mamwe marapirwo anogona kuvandudza mhedzisiro. Zvidzidzo zvenguva pfupi yapfuura zvakaratidza kuti mishonga yakaita secyclosporine, tumor necrosis factor alpha inhibitors, uye musanganiswa we intravenous immune globulin uye corticosteroids inogona kubatsira, zvichibva pamiyedzo inodzorwa uye kuongororwa kwezvidzidzo zvakawanda.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
 Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review 32520664 
NIH
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.